“The company will make a payment of $ 8.8 billion to $ 9.6 billion to resolve the current Roundup litigation, including an allocation expected to cover unresolved claims, and $ 1.25 billion to support a separate class agreement to address potential future litigation. “
Possible future cases will be governed by a class agreement that is subject to court approval, the company said.
Bayer said the settlement agreements “do not contain an admission of liability or irregularities.”
In each of those trials, jurors sided with the plaintiffs, saying Roundup was a substantial contributing factor in the plaintiffs’ cancer cause.
Bayer has appealed the verdicts in each of those three lawsuits. On Wednesday, the company said those cases “will continue during the appeals process and are not covered by the settlement.”
“It is important for the company to continue these cases as appeals will provide legal guidance in the future,” said Bayer.
Non-Hodgkin lymphoma patients began suing Monsanto in hundreds after a 2015 World Health Organization report suggested that glyphosate, the key ingredient in Roundup, could cause cancer.
“Leading health regulators worldwide have repeatedly concluded that Bayer’s glyphosate-based herbicides can be used safely as directed and that glyphosate is non-carcinogenic … including more than 100 studies ( la) EPA considered relevant to its cancer risk analysis, and more than 800 safety studies generally submitted to regulators, “Bayer said.
But critics question whether Monsanto had a cozy relationship with regulators, such as the Environmental Protection Agency.
.